Structural mechanism of sensing long dsRNA via a noncatalytic domain in human oligoadenylate synthetase 3

Jesse Donovan, Gena Whitney, Sneha Rath, and Alexei Korennykh

Department of Molecular Biology, Princeton University, Princeton, NJ 08544

Edited by Jennifer A. Doudna, University of California, Berkeley, CA, and approved February 24, 2015 (received for review October 8, 2014)

The mammalian innate immune system uses several sensors of double-stranded RNA (dsRNA) to develop the interferon response. Among these sensors are dsRNA-activated oligoadenylate synthetases (OAS), which produce signaling 2′,5′-linked RNA molecules (2-5A) that activate regulated RNA decay in mammalian tissues. Different receptors from the OAS family contain one, two, or three copies of the 2-5A synthetase domain, in which several instances evolved into pseudoenzymes. The structures of the pseudoenzymatic domains and their roles in sensing dsRNA are unknown. Here we present the crystal structure of the first catalytically inactive domain of human OAS3 (hOAS3.DI) in complex with a 19-bp dsRNA, determined at 2.0-Å resolution. The conformation of hOAS3.DI is different from the apo- and the dsRNA-bound states of the catalytically active homolog, OAS1, reported previously. The unique conformation of hOAS3.DI disables 2-5A synthesis by placing the active site residues nonproductively, but favors the binding of dsRNA. Biochemical data show that hOAS3.DI is essential for activation of hOAS3 and serves as a dsRNA-binding module, whereas the C-terminal domain DIII carries out catalysis. The location of the dsRNA-binding domain (DI) and the catalytic domain (DIII) at the opposite protein termini makes hOAS3 selective for long dsRNA. This mechanism relies on the catalytic inactivity of domain DI, revealing a surprising role of pseudoenzyme evolution in dsRNA surveillance.

dsRNA | OAS3 | RNase L | interferon | 2-5A

Interferon (IFN)-inducible oligoadenylate synthetases (OASs) are mammalian sensors of double-stranded RNA (dsRNA) that are transcriptionally up-regulated during infections with pathogens, such as Staphylococcus aureus (1) or H1N1 swine flu virus (2). Human cells express four related OAS family members: OAS1, OAS2, OAS3, and OASL. Whereas OASL is catalytically inactive, the remaining family members are dsRNA-activated enzymes synthesizing 2′,5′-linked oligoadenylates (2′,5′-A). The 2-5A serve as chemically unique second messengers that induce regulated RNA decay via RNase L (3, 4) and mediate antiviral and antibacterial innate immunity (5, 6). Here we report the structural and functional mechanism of dsRNA surveillance by the largest 2-5A synthetase, OAS3.

The core building unit of the OAS family is a polymerase beta (pol-β)-like nucleotidyl transferase domain, which shares structural similarity with poly-A polymerase, CCA-adding enzyme, and cytosolic dsDNA sensor cyclic GAMP synthetase (cGAS) (7, 8). Similar to these polymerases, OAS1 and OASL contain a single pol-β domain. However, OAS2 and OAS3 are unusual and contain two and three copies, respectively, acquired apparently by gene duplication (Fig. 1A) (9). The N-terminal pol-β-like domains of OAS2 and OAS3 see thought to have lost their enzymatic activity during evolution (3). In agreement with this hypothesis, mutagenesis of the C-terminal domains in OAS2 and OAS3 has been reported to inactivate these enzymes (10, 11).

The functions of the nonenzymatic domains in OAS2 and OAS3 are largely unknown. Experimental measurements of dsRNA binding to these domains are unavailable, with the exception of a qualitative study, which reported weak binding of the N-terminal domain of OAS2 to poly I:C-modified Sepharose beads (12). This observation suggests that the noncatalytic domain of OAS2 (and perhaps OAS3) may have lost both the catalytic function and the affinity for dsRNA.

Recent structural and biochemical studies of human OAS1 (hOAS1) revealed the mechanism of dsRNA recognition and activation of this enzyme via a conformational change (7, 13). Here we report, to our knowledge, the first crystal structure of the pseudoenzymatic domain D1 of human OAS3 (hOAS3.DI) in complex with dsRNA. This structure and complementary solution studies of hOAS3 and hOAS1 show that the duplicated noncatalytic domains have an essential role in recognition of long dsRNA by hOAS3.

Results and Discussion

Structure of hOAS3.DI Bound to dsRNA. Human OAS3 is a 121-kDa protein composed of three tandem OAS1-like domains, DI, DII, and DIII (Fig. 1A). To understand how hOAS3 employs these domains for sensing dsRNA, we attempted to crystallize full-length hOAS3 and its domains individually. Only domains DI, DII, and DIII, but not full-length hOAS3, could be purified in sufficient amounts, and only domain DI crystallized. Our crystallization conditions included a nonhydrolyzable ATP analog, AMPCPP, magnesium, and dsRNA with 19 base pairs (dsRNA19; Methods). Electron density for hOAS3.DI and dsRNA19 was clearly observed (Fig. 1B and Fig. S1), and the resulting structure of the hOAS3.DI×dsRNA19 complex was determined at 2.0-Å resolution (Table S1).

Significance

Double-stranded RNA (dsRNA) is a pathogen-associated molecular pattern that triggers the type-I interferon (IFN) response in mammalian cells. The IFN response up-regulates several dsRNA sensors, including closely related oligoadenylate synthetases (OAS). The functional roles of different oligoadenylate synthetases in dsRNA surveillance are not understood. Here, we use X-ray crystallography and biochemistry to demonstrate that human OAS1 and OAS3 recognize dsRNA molecules of different length. We show that domain duplication accompanied by a loss of catalytic activity provides the mechanism for sensing long dsRNA by OAS3. Our studies thus reveal different functions of OAS1 and OAS3 in dsRNA surveillance, identify a key role of domain duplication in the OAS family, and advance the fundamental understanding of the human innate immune system.

Author contributions: J.D. and A.K. designed research; J.D., G.W., S.R., and A.K. performed research; J.D., G.W., and S.R. contributed new reagents/analytic tools; J.D. and A.K. analyzed data; and J.D. and A.K. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

Data deposition: The atomic coordinates and structure factors reported in this paper have been deposited in the Protein Data Bank, www.pdb.org (PDB ID code 4S3N).

1To whom correspondence should be addressed. Email: akorenny@princeton.edu.

This article contains supporting information online at www.pnas.org/cgi/doi/10.1073/pnas.1419409112.

www.pnas.org/cgi/doi/10.1073/pnas.1419409112

PNAS | March 31, 2015 | vol. 112 | no. 13 | 3949–3954
As expected, the structure of hOAS3.DI has the nucleotidyl transferase fold and resembles the crystal structures of porcine and human OAS1 published previously (7, 13). The dsRNA19 molecule is bound to both N- and C-lobes of hOAS3.DI and resides on the opposite face from the active site-like pocket (Fig. 1B). In contrast to that of hOAS1 (7), the active site-like pocket of hOAS3.DI is unoccupied with magnesium ions or nucleotide.

Previous structural analysis of OAS1 (7) revealed that the conformational switch distinguishing the inactive (apo) and active (dsRNA-bound) states of this enzyme involves β-floor sliding, ratchet-like motion of helix αN5, and formation of a new helix αN4 in the active site (Fig. 2A). In the hOAS3.DI dsRNA19 complex reported here, the helix αN4 is present, but the β-floor/αN5 structure remains in the inactive-like conformation observed with apo-pOAS1. Comparison of hOAS1 with hOAS3.DI reveals that the β-floor/αN5 motion in hOAS3.DI may be limited due to two tryptophan residues, which anchor helix αN5 (Fig. S2A). Therefore, hOAS3.DI has a hybrid conformation, which combines elements of active and inactive states of OAS1.

The key to activation of 2-5A synthesis by hOAS1 is the assembly of the active site residues into a compact structure (7), which enables recruitment of Mg2+ ions and ATP (Fig. 2B Left vs. Right). A similar mechanism is responsible for activation of another pol-β-like enzyme, cGAS, which serves as a sensor of cytosolic dsDNA (8). In contrast to these examples, hOAS3.DI does not place the equivalent active site residues compactly even in the presence of dsRNA19 (Fig. 2B). This feature should disable the dsRNA-dependent catalytic switch and block 2-5A synthesis.

Biochemical Dissection of hOAS3 Defines Domain DI as a Pseudoenzyme with Enhanced dsRNA Binding. Analysis of amino acid conservation revealed that key active site aspartate residues equivalent to D75, D77, and D148 of hOAS1 (Fig. 2B) are not conserved in domains DI and DII of hOAS3, which presumably leads to enzymatic inactivity of these domains (10). To experimentally define how each domain of hOAS3 functions in 2-5A synthesis, we expressed and purified all individual domains and assayed their activity with and without dsRNA. We used poly I:C as a model dsRNA (Fig. 3A).

None of the purified domains synthesized 2-5A under the conditions that activate hOAS1 (7) (Fig. 3A; poly I:C and MgCl2 data). A similar observation has been reported for hOAS2: neither domain hOAS2.DI nor hOAS2.DII is active when expressed individually (12). Together, these results suggest that 2-5A synthesis by hOAS2 and hOAS3 may require the intact proteins. However, upon further experimentation we found that addition of Mn2+ ions activates rapid, dsRNA-dependent 2-5A synthesis by hOAS3.DIII (Fig. 3A, last lane). The mechanism of hOAS3.DIII activation by Mn2+ ions is presently unknown. However, reactions in the presence of Mn2+ allow, to our knowledge for the first time, studies of 2-5A synthesis by a single domain from the OAS family, other than OAS1. Our data show that the isolated domain hOAS3.DIII is fully sufficient for 2-5A synthesis and is functionally similar to
hOAS3. Intact hOAS3, which contains all three domains, is not strictly required for 2-5A synthesis. Domains DI and DII remain inactive under all conditions tested (Fig. 3A). Complementary analysis shows that domains DI and DII do not carry out 2-5A synthesis in the context of full-length hOAS3 as well. The active site mutations D148A and D188A in domain DIII render full-length hOAS3 catalytically inactive (Fig. 3B), in full agreement with an independently conducted recent study of hOAS3 (11). The catalytic inactivity of domains DI and DII could be most simply explained by the loss of sequence conservation and mutations of the catalytic aspartate residues (10). To test this hypothesis, we mutated the active site aspartates in hOAS1 to the corresponding residues of hOAS3 (Fig. 2B, Left vs. Center). A single mutation D144S had a minor effect, but the double mutant D148S+D77E, and the control double mutant D75A+D77A inactivated hOAS1, as expected (Fig. 3C, hOAS1). Notably, the reverse experiment that restores the aspartate residues in the active site of hOAS3.DI does not rescue 2-5A synthesis (Fig. 3C, hOAS3.DI). Therefore, the loss of the aspartate conservation does not fully explain the catalytic inactivity of hOAS3.DI. These results and the crystal structure of hOAS3.DI•dsRNA19 indicate that hOAS3.DI lacks enzymatic activity largely due to the inactive conformation of the catalytic center (Fig. 2B).

Although hOAS3.DI is catalytically inactive, the co-crystal structure with dsRNA19 demonstrates that this protein retains the ability to bind dsRNA (Fig. 1B). It is unknown whether the dsRNA-binding affinity is comparable to that of the catalytically active 2-5A synthetases, such as hOAS1, or compromised as a result of hOAS3.DI becoming a pseudoenzyme. To resolve this uncertainty and understand the function of the pseudoenzymatic domains of OAS3, we evaluated the binding of dsRNA to hOAS3.DI. To this end we used dsRNA with 18 base pairs (dsRNA18; Methods) as a model RNA duplex, and inhibition of hOAS1 activity by hOAS3.DI as a readout. We found that dsRNA18 binds to hOAS3.DI ~14-fold stronger than to hOAS1 (Kd,hOAS1 = 50 μM vs. Kd,hOAS3.DI = 3.1 μM, Fig. 3D; a similar ~10-fold difference is observed using Kd,hOAS1 (Kd,hOAS1 = 26 μM; Fig. S2 B and C). To confirm that the inhibition by hOAS3.DI results from the binding to dsRNA, we prepared two control mutants, R30A and R41A. Both mutants disrupt the hOAS3.DI/dsRNA interface in the crystal structure (Fig. S2D). As expected, hOAS3.DI with R30A or R41A mutations no longer inhibits hOAS1 (Fig. 3D, Right). The modest (~3.5-fold) rate enhancement observed with the R30A mutant (Fig. 3D) must arise from modulating the activity of hOAS1, as the mutation per se does not render hOAS3.DI catalytically active (Fig. S2E).

The stronger binding of dsRNA to hOAS3.DI than to hOAS1 cannot be straightforwardly explained by comparing the respective protein/RNA interfaces. In the crystal structures, hOAS3.DI buries less surface area (2,588 Å² for hOAS3.DI vs. 3,039 Å² for hOAS1, PDB ID code 4IG8), and forms noticeably fewer contacts with dsRNA (Fig. S3). The enhanced binding of dsRNA to hOAS3.DI presumably arises from the conformational properties of hOAS3.DI, which binds dsRNA without fully abandoning the inactive-like conformation (Fig. 2A). Because the dsRNA-induced conformational changes in the proteins and the binding affinity of dsRNA are thermodynamically coupled, a less costly conformational rearrangement in hOAS3.DI should lead to a stronger binding of dsRNA. Together, our structural and functional data suggest that the hybrid conformation of hOAS3.DI not only disables 2-5A synthesis, but also favors the binding of dsRNA.

**Domain DI Drives Recognition of Long dsRNA by hOAS3.** Domain DI is located at the N terminus, whereas the only catalytically active domain DIII resides at the C terminus of hOAS3. It is possible that hOAS3 wraps around the dsRNA target and uses domain DI to enhance the binding affinity, providing avidity (11). Alternatively, hOAS3 could remain extended, as suggested by SAXS envelope obtained with free OAS3 (11), which would use domain DI for recognition of longer dsRNA (Fig. S4A). To understand the mechanism of dsRNA sensing by hOAS3, we analyzed recognition of long, medium, and short dsRNA targets by this receptor. As a reference, we examined activation of hOAS1, which binds to ~17 base pairs in the crystal structure (7) and should optimally recognize short dsRNA with fewer than 20 base pairs. To examine recognition of long dsRNA, we used poly I:C as a model activator. Due to the heterogeneity of poly I:C (Fig. S5A; average length ~120–130 bp), we expressed the dsRNA concentration in units of OD260. At saturating concentrations of poly I:C, hOAS1 and hOAS3 have similar specific activities of 2-5A synthesis (Fig. 4A). However, poly I:C titration reveals that hOAS3 binds long dsRNA ~18-fold stronger than does hOAS1, indicating that hOAS3 is considerably more sensitive to long dsRNA. Notably, deletion of domain DI nearly abolished the catalytic activity of hOAS3 (Fig. 4B). The ΔDI mutant (residues 404–1087) exhibits a ~30-fold smaller specific activity at saturating concentrations of poly I:C, and binds dsRNA ~1.4-fold weaker (Fig. 4C). A manganese rescue experiment confirmed that the loss of dsRNA sensing by the ΔDI mutant is not due to nonspecific effects, such as protein misfolding, as ΔDI is intrinsically functional (Fig. S5B). Therefore, domain DI is critical for activation of hOAS3 by poly I:C, and must serve as a dsRNA-binding module. Deletion of the second pseudoenzymatic domain, DII, has a negligible impact on 2-5A synthesis, suggesting that domain DII serves as a spacer between domains DI and DIII (Fig. 4B, ΔDI vs. hOAS3.DIII). This model is further supported by mutagenesis of full-length hOAS3. Mutation K435A in domain DII, which removes a predicted dsRNA-binding basic residue, has a minor effect on activation of hOAS3 (Figs. S3 and S5C).
To probe activation of hOAS3 by medium-size dsRNA, we partially digested poly I:C with RNase III and purified products that contain 50 base pairs or less (Fig. S5A). The medium-size poly I:C had nearly the same binding preference for hOAS3 versus hOAS1 (~14-fold; Fig. S4) as observed above with long poly I:C (~18-fold; Fig. 4). The maximum specific activity of hOAS1 bound to medium and long poly I:C was also similar (Fig. 5B). However, the maximum specific activity measured with hOAS3 was ~50-fold lower with medium-size poly I:C compared with long poly I:C (Fig. 5B). These results show that hOAS1 does not discriminate between long and medium-size poly I:C, whereas hOAS3 has a strong preference for dsRNA with more than 50 base pairs.

The preference for long poly I:C suggests that hOAS3 should have a linear arrangement of domains upon binding to dsRNA (Fig. S4A). Considering that a single domain of a 2-5A synthetase can accommodate ~17–20 base pairs (Fig. 1B), <50-bp poly I:C should dock to two hOAS3 domains at a time and bind either to domains DI+DII or to domains DII+DIII (Fig. S5D). We have shown that the tandem DII+DIII binds dsRNA poorly (Fig. 4 B and C). Therefore, poly I:C with fewer than 50 base pairs should dock predominantly to domains DI+DII. This mechanism leaves the catalytic domain DIII mostly unoccupied and explains the low specific activity of hOAS3 observed in Fig. 5. Of note, the sensitivity of the OAS enzymes to dsRNA length may additionally arise, at least in part, from mechanisms that include assembly of hOAS3 oligomers or filaments on long dsRNA, as observed with MDA-5 (14). We do not expect that hOAS3 oligomerization has a major role, as we do not observe a cooperative activation of this protein (Fig. S4B).

Finally, we compared activation of hOAS3 and hOAS1 by transcribed dsRNA of defined sequence, using dsRNA18 and dsRNAs4 as model substrates. Human OAS3 again exhibited a stronger preference for longer dsRNA compared with hOAS1 (Fig. 5B and Fig. S6A and B). Together, our data show that hOAS3 is functionally distinct from hOAS1 and serves as a sensor of dsRNA with ~50 base pairs or more. The different dsRNA length requirements of hOAS3 and hOAS1 suggest nonoverlapping biological functions of these receptors, which could explain the diversity of 2-5A synthetases in genomes of higher vertebrates (Fig. 4A).

**Probing with hOAS3 and hOAS1 Reveals Relatively Long Endogenous dsRNA in HeLa Cells.** Pathogens are the most commonly described sources of intracellular dsRNA, however, mammalian cells also contain endogenous dsRNA molecules. It has been shown that nuclear RNA purified from leukemia cells can activate mixed 2-5A synthetases (15), whereas total RNA from HeLa cells can activate purified hOAS1 in vitro (16). The size of the endogenous dsRNA structures detected in these experiments is unknown and difficult to evaluate experimentally. The selectivity of hOAS3 for long dsRNA suggests a simple and potentially broadly applicable approach for detection of long dsRNA elements in heterogeneous RNA samples. We used this approach to examine endogenous dsRNA purified from human epithelial (HeLa) cells.

To evaluate the dsRNA size, we carried out a study with both hOAS1 and hOAS3. Our experiments confirmed the presence of hOAS1 activators in total HeLa RNA (Fig. S7A, lanes 11–13). Next, we experimentally determined the concentration of poly I:C and dsRNA18 to match the specific activity observed with HeLa RNA (Fig. S7A, lanes 6–13). We selected the concentration of poly I:C and dsRNA18 to match the specific activity observed with HeLa RNA (Fig. S7A, lanes 6–13). Next, we experimentally determined the concentration of hOAS3 that matches the rate of hOAS1 in the presence of poly I:C (Fig. S7A, lanes 20–22 vs. 8–10), and tested the effect of dsRNA18 and total HeLa RNA at this hOAS3 concentration. As expected, dsRNA18 barely activated hOAS1 (Fig. S7A, lanes 17–19 vs. 5–7). However, total HeLa RNA had a noticeably stronger effect (Fig. S7A, lanes 23–25 vs. 18–20), although the activation was not as strong as with poly I:C. These data suggest that the endogenous dsRNA species present in
HeLa cells should be shorter than the effective size of poly I:C (<120–130 bp), but longer than dsRNA18 (>20 bp).

We note that our analysis of dsRNA presence is accurate only if hOAS1 and hOAS3 are not activated by single-stranded RNA (ssRNA) present in HeLa samples. However, OAS1 has been reported to synthesize 2-5A in the presence of both dsRNA and ssRNA (17). On close inspection, we noticed that ssRNA activators of OAS1 were obtained using transcription with T7 RNA polymerase, which can produce contaminating dsRNA by reading the primary transcript as a template (18, 19). To verify whether hOAS1 or hOAS3 can indeed be activated by ssRNA, we examined two ssRNA samples. One was transcribed with T7 RNA polymerase (ssT7) and the other obtained by chemical synthesis (ssD). Only ssT7 could activate hOAS1 and hOAS3, whereas ssD had no detectable activity (Fig. S7B). Therefore, hOAS1 and hOAS3 are exquisitely selective for dsRNA and can be used for dsRNA detection even in the presence of ssRNA.

Double-stranded RNA elements with fewer than 20 base pairs are relatively abundant in coding RNA (7); however, the dsRNA molecules detected in total HeLa RNA are longer and could arise from other sources, such as transcription of centromeric satellite DNA, antisense transcription, or additional mechanisms that can produce complementary RNA (20). If these dsRNA elements can become accessible to the OAS region in vivo, they could have homeostatic functions, which may explain increased basal OAS expression in human organs, such as thymus and bone marrow (21).

Conclusions

We show that hOAS3 is potently activated by dsRNA with more than 50 base pairs, which suggests that the specific role of hOAS3 is to sense long dsRNA. The discrimination between short and long dsRNA requires all three domains of hOAS3. The C-terminal domain DIII is the only catalytically active domain that carries out 2-5A synthesis in response to dsRNA (Fig. 6A). Domain DI is also a pseudoenzyme, but with a high affinity for dsRNA. This arrangement makes hOAS3 sensitive only to sufficiently long dsRNA molecules, which span from domain DI to domain DIII. Domain duplication and the loss of catalysis in the duplicated domains thus provide a surprising mechanism for bypassing short and medium-size dsRNA, and activation of OAS3 only by long dsRNA.

The crystal structure of the hOAS3 DI−dsRNA19 complex provides, to our knowledge, the first atomic view of a pseudoenzyme from the OAS family. The unusual conformation of hOAS3.DI prevents catalysis even in the presence of dsRNA, but favors the binding of dsRNA. This observation suggests an evolutionary tradeoff between regulated 2-5A synthesis and strong dsRNA binding, both of which depend on the conformational properties of hOAS3.DI. This tradeoff is consistent with the escape from adaptive conflict model, wherein a protein with more than one function cannot improve one function (dsRNA binding) without sacrificing the other (2-5A synthesis), thereby necessitating gene or domain duplication (22).

The functions of the catalytically inactive domains in OAS2 and OASL await future characterization, but analogy with hOAS3.DI suggests that these domains could serve as potent dsRNA recruitment modules. Recently, it has been established that OASL forms a complex with RIG-I, a sensor of dsRNA with a helicase domain, and enhances its signaling (23). The role of OASL in the OASL—RIG-I complex may parallel that of domain DI in hOAS3, and render RIG-I sensitive to longer dsRNA.

Previous studies of mammalian oligoadenylate synthetases focused largely on the enzymatically active domains. Here we show that the noncatalytic domains of hOAS3 have an essential function and drive recognition of long dsRNA. Among four human oligoadenylate synthetases, three have noncatalytic domains, arranged uniquely in each sensor. Our results suggest that these domains should give distinct specificities to oligoadenylate synthetases and determine their roles in the IFN response.

Methods

DNA Plasmids. The coding region of human OAS3 was amplified by PCR from an in-house cDNA library using poly I:C transfected HeLa cells and cloned into pGEX-6p vector. Sequencing revealed the clone to have a naturally occurring Tyr743Stop mutation. The DIII construct was created by deleting the coding region for OAS3 residues 1–130 bp, whereas the DII construct was generated by deleting the coding region for OAS3 residues 1–80 bp. The construct for OAS3 DII was made using site-directed mutagenesis that introduced the Leu372Stop mutation. The DII construct was generated by deleting the coding region for OAS3 residues 1–80 bp. The construct for OAS3 DI was used making site-directed mutagenesis that introduced the Leu743Stop mutation. The DII construct was created by deleting the coding region for OAS3 residues 1–742. Plasmids for full length (1–1087) and ΔDI OAS3 (residues 404–1087) were encoded by c-terminal 6×His-tagged added by site-directed mutagenesis. The human OAS1 construct in pGEX-6p encoding residues 1–346 has been described (7). All constructs used in this study were verified by DNA sequencing.

Protein Purification. Human OAS1 was purified as described (7). Individual domains of OAS3 were purified as described for human OAS1. Escherichia coli BL21 Codon Plus RIL (Applied Biosystems) transformed with plasmids encoding C-terminally 6×His-tagged full-length or ΔDI OAS3 were grown in LB at 22°C until OD600 = 1 and induced with 1 mL of 60 mg/mL IPTG per L of culture. Bacteria were harvested and the cell pellets were lysed in buffer A (20 mM Hesper pH 7.5, 500 mM NaCl, 10% (vol/vol) glycerol, 0.1 mM EDTA, 2 mM DTT, 30 mM imidazole, 1% Triton X-100, 1× Roche complete protease...
inhibitors) using Avestin EmulsiFlex C3. Cell lysates were cleared by centrifugation at 35,000 x g for 30 min at 4 °C. Proteins were purified on Nickel Superflow (Clontech) followed by size-exclusion chromatography on FPLC. Full-length and ΔΔI OAS3 were further purified by MonoS ion-exchange chromatography and then exchanged into buffer A without Triton X-100 and imidazole. Protein concentrations were quantified by UV spectrophotometry. ΔΔI construct was quantified by band densitometry of SDS/PAGE gels, using BSA as a standard.

Double-Stranded RNA. Short synthetic dsRNAs used for kinetic assays and crystallography were purchased as individual strands from Dharmaco. Duplexes were generated by annealing the ssRNAs. Poly I:C was purchased from Sigma. All RNAs were dissolved in RNA buffer (20 mM Hepes pH 7.5, 100 mM NaCl). Sequences of dsRNA used: 5′-GGAAUUGACCUUUAUGC-3′ (top strand of dsRNA18); 5′-GGCUUUGACCUUUAUGAA-3′ (top strand of dsRNA19). In vitro transcribed ssT7 (Fig. 5B7), its reverse complement, and both strands of dsRNA45 were synthesized with the MegashortScript kit (Invitrogen) using purified PCR-DNA template. Transcripts were phenol-chloroform extracted and PAGE-purified before the use in OAS assays.

RNase III Digest. Poly I:C (200 μg) was incubated with 0.08 μL U/mL ShortCut RNase III (New England Biolabs) for 1 h at 37 °C. Reactions were stopped with EDTA according to the manufacturer’s protocol, phenol:chloroform (1:1) extraction, and ethanol precipitation in the presence of 10 μL glycogen. Digested poly I:C was separated by electrophoresis using a 4% agarose gel, and the RNA was excised. Poly I:C was recovered by the freeze and squeeze method. Briefly, gel slices in 1.5-mL microfuge tubes were covered with TE buffer pH 7.5, melted at 95 °C, and frozen at −80 °C for 10 min. After freezing the samples were centrifuged at 21,130 × g at 4 °C and 10% FBS at 37 °C with 37 °C. Proteins were purified on Nickel agarose. OAS Activity Assays. Kinetics analyses were carried out at 37 °C using the concentrations of dsRNA and OAS proteins indicated for each experiment. Reactions contained 20 mM Hepes pH 7.5, 70 mM NaCl, 5 mM MgCl2 (or 5 mM MnCl2 when indicated), 10% (vol/vol) glycerol, 4 mM DTT, and 0.05% Triton X-100. Reactions were done and analyzed as described (7). Observed rate constants (k_{obs}) were determined by single-exponential decay fitting in SigmaPlot. Binding constants were obtained from hyperbolic fit to the equation $k_{obs} = k_{max} [dRNA] / (K_d + [dRNA])$. Activation efficiency was calculated as $k_{obs_{activ}} / k_{obs_{unactivated}}$, and represents the ratio of specific activity to dRNA binding affinity. Of note, although the titrations $k_{obs}$ vs. [dRNA] result in Michaelis-Menten-like profiles, these titrations measure $K_d$ rather than $K_m$, because dsRNA is not a substrate or an enzyme, but an activator in the reaction.

Cell Culture. HEK293 cells were cultured in MEM + 10% FBS at 37 °C with a humidified 5% CO2 atmosphere. Total RNA was extracted using TRIzol from cultures at ~90% confluence.

OAS3/DI+dsRNA19 Crystallization. Crystallization complexes contained 20 mg/mL DI, 82 μM dsRNA19, 5 mM AMPCP, 10 mM MgCl2, 142 mM NaCl, and 1.43 mM Hepes pH 7.5. Crystals were grown using the hanging drop vapor diffusion method by mixing the crystallization Complex 1:1 with reservoir solution (200 mM sodium citrate, 150 mM NaCl, 12% PEG 3350). Crystals were transferred in cryo-protectant (200 mM sodium citrate, 12% PEG 3350, 25% ethylene glycol) and frozen in liquid nitrogen.

X-Ray Data Collection and Structure Determination. X-ray diffraction data were collected using beamline X29 at the National Synchrotron Light Source (Brookhaven National Laboratory). Data were collected at wavelength 1.075 Å. Data were processed with the XDS package (24). Crystals contain one DI+dsRNA binary complex in the asymmetric unit and belong to the monoclinic P2121 space group (Table S1). The structure was solved by molecular replacement using Phaser using hOAS1 (PDB code 4I3G) as the search model. The structure was modeled in COOT (25) and refined by simulated annealing using PHENIX (26). The orientation of dsRNA was determined by refining the data against a model in which the dsRNA was built in the opposite direction (Fig. S1). The final model has good stereochemical parameters and no Ramachandran outliers (Table S1).

Acknowledgments. We thank the staff at the National Synchrotron Light Source, beam line X29, for on-site help and members of the A.K. laboratory for insightful discussions and feedback during writing. We also thank Professor Andrei Korostelev for reading and commenting on the finished manuscript and the reviewers for making valuable suggestions. This study was funded by Princeton University, NIH Grant 1R01GM110161-01 (to A.K.), Sidney Kimmel Foundation (to A.K.), and Burroughs Wellcome Foundation (to A.K.).